| Active substance | olipudase alfa |
| Holder | Sanofi |
| Status | Closed |
| Indication | acid sphingomyelinase deficiency for patients who have participated and exit the clinical studies DFI-12712-ASCEND or LTS-13632 |
| Public documents | Approbation |
| Approbation amendment | |
| Information for the patient | |
| Informed consent | |
| Last update | 27/05/2024 |